c-myc, not her-2/ neu, can predict the prognosis of breast cancer patients : how novel, how accurate, and how significant?

• Autor(a) principal: Schmitt, Fernando C.
• Data de Publicação: 2003
• Outros Autores: Reis Filho, Jorge S.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/1822/1924
• topic: c-erbB-2; Prognosis; c-myc; her-2/neu; Oncogene; Polymerase chain reaction; Science & Technology

The predictive and prognostic implication of oncogene amplification in breast cancer has received great attention in the past two decades. her-2/neu and c-myc are two oncogenes that are frequently amplified and overexpressed in breast carcinomas. Despite the extensive data on these oncogenes, their prognostic and predictive impact on breast cancer patients remains controversial. Schlotter and colleagues have recently suggested that c-myc, and not her-2/neu, could predict the recurrence and mortality of patients with node-negative breast carcinomas. Regardless of the promising results, caution should be exercised in the interpretation of data from studies assessing gene amplification without in situ analysis. We address the novelty, accuracy and clinical significance of the study by Schlotter and colleagues.